How Does Car T Cell Therapy Work Steps And Effects?

CAR T cell therapy is a personalized cancer treatment that re-engineers a patient’s own immune cells to attack their cancer. The process involves collecting T cells from the patient’s blood, genetically modifying them in a lab to recognize cancer cells, and infusing them back into the patient. Once inside the body, these modified cells multiply and seek out and destroy cancer cells carrying a specific marker. This therapy is currently approved for certain blood cancers, and it works in distinct steps with a unique set of side effects that differ from standard chemotherapy.

What Are T Cells and Why Use Them?

T cells are a type of white blood cell that normally patrol the body looking for infected or abnormal cells. They are a core part of the immune system’s ability to fight off viruses and other threats. Cancer cells, however, often find ways to hide from T cells or suppress their activity, allowing tumors to grow unchecked.

CAR T cell therapy takes these natural killer cells and gives them a new tool. The “CAR” stands for chimeric antigen receptor. This is a synthetic protein engineered in a laboratory. When added to a T cell, it allows the cell to recognize a specific protein on the surface of cancer cells. Most approved CAR T therapies target a protein called CD19, which is found on B cells, including cancerous B cells in certain leukemias and lymphomas.

This approach is highly targeted compared to chemotherapy. Chemotherapy kills rapidly dividing cells throughout the body, while CAR T cells are designed to attack a specific cancer type with a specific marker. This precision is why the therapy has been so successful in some hard-to-treat blood cancers.

Step 1: Collecting the Patient’s T Cells

The first step is a process called leukapheresis. The patient is connected to a machine that draws blood, separates out the white blood cells, and returns the remaining blood components back to the body. This is similar to donating platelets or plasma but takes several hours.

The collected white blood cells are then sent to a specialized manufacturing facility. From this mixture, the T cells are isolated and prepared for genetic modification. The entire process is personalized because the cells come from the individual patient. This means the therapy cannot be given to anyone else.

The collection process itself is generally well-tolerated. Some patients may feel lightheaded or experience numbness in their fingers or lips due to the citrate used to prevent clotting during the procedure. These effects are temporary and resolve once the procedure is complete.

Step 2: Engineering the CAR T Cells in the Lab

In the laboratory, the patient’s T cells are genetically modified to produce the chimeric antigen receptor. This is typically done using a disabled virus, often a lentivirus or retrovirus, that has been engineered to carry the genetic instructions for the CAR. The virus delivers this genetic material into the T cells’ DNA, causing them to produce the CAR protein on their surface.

This step is a true genetic engineering process. The modified T cells are then multiplied in large numbers in the lab. It can take two to three weeks to grow enough CAR T cells for a single treatment dose. The final product is frozen and shipped back to the hospital where the patient is being treated.

This manufacturing window is a critical period. During this time, the patient may receive “bridging therapy” to keep their cancer under control. This is often a short course of chemotherapy or other medication to prevent the disease from progressing while the CAR T cells are being made.

Step 3: Conditioning Chemotherapy Before Infusion

Before the CAR T cells are infused, the patient receives a short course of chemotherapy. This is not meant to kill the cancer. Instead, it is called lymphodepleting chemotherapy. Its purpose is to reduce the number of existing immune cells in the body, making room for the new CAR T cells to expand and function effectively.

This conditioning regimen usually lasts a few days. Common drugs used include fludarabine and cyclophosphamide. By clearing out the existing lymphocytes, the body’s immune environment becomes more favorable for the infused CAR T cells to grow and multiply.

This step is important for the therapy’s success. Without lymphodepletion, the CAR T cells often do not expand enough in the body to produce a strong anti-cancer response. The conditioning chemotherapy is generally well-tolerated, though it can cause temporary drops in blood counts, which may increase the risk of infection.

Step 4: Infusion of CAR T Cells

The infusion itself is similar to a blood transfusion. The frozen CAR T cells are thawed and given to the patient through an intravenous line. The infusion typically takes less than an hour. Patients are closely monitored during and after the infusion for any immediate reactions.

Once infused, the CAR T cells travel through the bloodstream and begin to encounter cancer cells. The CAR receptor on their surface binds to the target protein on the cancer cells, triggering the T cell to become activated. This activation causes the T cells to multiply rapidly and release substances that kill the cancer cells.

This expansion phase is a critical indicator of the therapy’s effectiveness. Patients who show a strong expansion of CAR T cells in their blood often have a better response. The entire process from collection to infusion typically takes about three to four weeks.

What Happens After Infusion: The Effects

The days and weeks following the infusion are the most critical period. The activated CAR T cells are now actively killing cancer cells. This process is effective, but it triggers a strong immune response that can cause significant side effects. The two most common and serious effects are cytokine release syndrome and neurotoxicity.

Cytokine release syndrome (CRS) occurs when the activated CAR T cells release large amounts of cytokines, which are signaling molecules that cause inflammation. This can lead to fever, low blood pressure, and difficulty breathing. In severe cases, CRS can be life-threatening. It is managed with medications like tocilizumab, which blocks the effects of a key cytokine called IL-6, and sometimes steroids.

Neurotoxicity is another common side effect. It can cause confusion, tremors, difficulty speaking, and in rare cases, seizures. The exact cause is not fully understood, but it appears to be related to the inflammatory response. Most neurological side effects are temporary and resolve as the immune response calms down.

Other side effects include an increased risk of infections because the therapy depletes normal B cells, which are important for producing antibodies. Patients may also experience low blood counts, fatigue, and a weakened immune system for several months after treatment.

How Effective Is CAR T Cell Therapy?

CAR T cell therapy has produced remarkable results in certain blood cancers, particularly in patients who have not responded to other treatments. In some clinical trials, a significant percentage of patients with relapsed or refractory B-cell acute lymphoblastic leukemia and large B-cell lymphoma have achieved complete remission, meaning no cancer is detectable after treatment.

However, the therapy is not a guaranteed cure. Some patients will relapse after a period of time. The durability of the response varies from person to person. Researchers are actively studying why some patients have long-lasting remissions while others do not.

The therapy is also currently limited to specific types of blood cancers. It has not been shown to be effective for solid tumors like breast, lung, or colon cancer. This is largely because solid tumors create a hostile environment that suppresses immune cells, and they do not have a single target like CD19 that is present on all cancer cells. Research is ongoing to overcome these barriers, but no CAR T therapy is currently approved for solid tumors.

Who Can Receive CAR T Cell Therapy?

CAR T cell therapy is not a first-line treatment. It is typically reserved for patients who have failed at least two prior lines of therapy for their blood cancer. It is approved for certain types of non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia in children and young adults, and multiple myeloma.

Eligibility also depends on the patient’s overall health. Because the therapy carries significant risks, including severe CRS and neurotoxicity, candidates must have adequate organ function and be well enough to tolerate the treatment. Older adults and those with significant medical conditions may be evaluated on a case-by-case basis.

Cost is a significant barrier. The therapy is expensive, often exceeding several hundred thousand dollars before hospital costs and supportive care. Many insurance plans cover it, but prior authorization and financial assistance programs are often needed.

What Are the Long-Term Risks?

Long-term risks are still being studied because the therapy has only been in widespread use since 2017. One known long-term effect is prolonged B-cell depletion. Because CAR T cells target CD19, which is present on all B cells, the therapy destroys both cancerous and healthy B cells. This means patients may need immunoglobulin replacement therapy to prevent infections for months or years after treatment.

There is also a small risk of secondary cancers. Because the genetic modification uses a virus to insert the CAR gene, there is a theoretical risk of the virus inserting into a location in the DNA that could cause a new cancer. This risk appears to be very low, but it is monitored in patients who receive the therapy.

Patients who receive CAR T cell therapy should have long-term follow-up with their oncology team. This includes regular blood tests to monitor immune function and scans to check for cancer recurrence. The therapy is still relatively new, and researchers continue to track outcomes in patients who received it years ago.